Emerging data about HR DNA repair mechanisms in CRPC suggest that in a context of HR integrity, ADT can affect HR prior to the development of castration resistant status, and that the combination of PARP inhibitors with ADT could be beneficial in advanced or high-risk prostate cancer [28,53]. The gene discussed is PARP1; the disease is prostate carcinoma.